PMID- 2045866
OWN - NLM
STAT- MEDLINE
DCOM- 19910718
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 9
IP  - 7
DP  - 1991 Jul
TI  - Phase I study of liposomal MTP-PE-activated autologous monocytes administered 
      intraperitoneally to patients with peritoneal carcinomatosis.
PG  - 1251-60
AB  - We have conducted a phase I study with autologous monocytes activated ex vivo and 
      administered intraperitoneally in nine patients with peritoneal carcinomatosis. 
      Blood monocytes were collected by leukapheresis and then purified by counterflow 
      elutriation (up to 10(9) cells, with a purity of greater than 90%). Ex vivo 
      activation was obtained by incubating these cells with 1 micrograms liposomal 
      MTP-PE/10(6) monocytes for 18 hours in hydrophobic culture bags at 37 degrees C 
      in 5% carbon dioxide humidified air. The activated monocytes were then infused in 
      the peritoneal cavity once a week for 5 consecutive weeks through an implanted 
      peritoneal infusion system, Port-A-Cath (Pharmacia Deltec, St Paul, MN), on an 
      intrapatient dose-escalating schedule (10(7) to 10(9) monocytes). No severe 
      adverse reactions occurred. Toxicity was mild, the chief acute reactions being 
      fever (27%), chills (13%), and abdominal pain (25%). None of the side effects led 
      to dose reduction. No consistent change in hemostatic function, liver function, 
      or renal function was observed. Significant increases in granulocyte counts, 
      neopterine, and acute phase reactants (fibrinogen, C-reactive protein) occurred 
      in the peripheral blood. In vitro monocyte activation was demonstrated by the 
      relapse of procoagulant activity and monokines (interleukin-1 [IL-1], IL-6, and 
      tumor necrosis factor-alpha [TNF alpha]) in the supernatants of cultured 
      monocytes. Evidence for in vivo monocyte activation was provided by the increase 
      of these monokines in the peritoneal fluids. Kinetic studies with indium-111 
      (111In)-labeled activated autologous monocytes in five patients suggest that 
      these infused monocytes may remain in the peritoneal cavity for up to 7 days. 
      This locoregional immunotherapeutic approach seems to be encouraging in view of 
      adjuvant therapeutic modality in ovarian cancer patients with minimal residual 
      intraabdominal disease following second-look laparotomy.
FAU - Faradji, A
AU  - Faradji A
AD  - Department of Medical Hematology and Oncology, University Hospital Hautepierre, 
      Strasbourg, France.
FAU - Bohbot, A
AU  - Bohbot A
FAU - Frost, H
AU  - Frost H
FAU - Schmitt-Goguel, M
AU  - Schmitt-Goguel M
FAU - Siffert, J C
AU  - Siffert JC
FAU - Dufour, P
AU  - Dufour P
FAU - Eber, M
AU  - Eber M
FAU - Lallot, C
AU  - Lallot C
FAU - Wiesel, M L
AU  - Wiesel ML
FAU - Bergerat, J P
AU  - Bergerat JP
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Indium Radioisotopes)
RN  - 0 (Liposomes)
RN  - 0 (Monokines)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Blood Cell Count
MH  - Carcinoma/blood/etiology/pathology/*therapy
MH  - Drug Evaluation
MH  - Female
MH  - Humans
MH  - Indium Radioisotopes
MH  - Infusions, Parenteral/instrumentation
MH  - Liposomes
MH  - Male
MH  - Middle Aged
MH  - *Monocytes, Activated Killer
MH  - Monokines/blood
MH  - Peritoneal Neoplasms/blood/etiology/pathology/*therapy
MH  - Regression Analysis
MH  - Time Factors
EDAT- 1991/07/01 00:00
MHDA- 1991/07/01 00:01
CRDT- 1991/07/01 00:00
PHST- 1991/07/01 00:00 [pubmed]
PHST- 1991/07/01 00:01 [medline]
PHST- 1991/07/01 00:00 [entrez]
AID - 10.1200/JCO.1991.9.7.1251 [doi]
PST - ppublish
SO  - J Clin Oncol. 1991 Jul;9(7):1251-60. doi: 10.1200/JCO.1991.9.7.1251.